VILIP-1 (Visinin-Like Protein 1)
Introduction
Vilip 1 (Visinin Like Protein 1) Neuronal Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
VILIP-1 (Visinin-Like Protein 1), also known as VSNL1, is a neuronal calcium sensor protein that serves as a biomarker for neuronal injury in Alzheimer's disease and other neurodegenerative disorders[@laterza2006].
Overview
VILIP-1 belongs to the neuronal calcium sensor (NCS) family of proteins, which are expressed primarily in neurons and involved in calcium-dependent signaling pathways. In the brain, VILIP-1 is found in hippocampal pyramidal neurons, cortical neurons, and cerebellar granule cells[@bernstein1999]. CSF and plasma VILIP-1 levels reflect the degree of neuronal damage and have emerged as a promising biomarker for neurodegenerative diseases.
Structure and Function
Molecular Characteristics
| Property | Value |
|----------|-------|
| Gene | VSNL1 (Visinin-Like 1) |
| Protein Name | Visinin-like protein 1 (VILIP-1) |
| UniProt ID | P62760 |
| Molecular Weight | ~22 kDa |
| Brain Expression | Hippocampus, Cortex, Cerebellum |
| Cellular Localization | Cytosolic, membrane-associated |
Normal Physiological Function
VILIP-1 participates in several neuronal processes[@burgoyne2007]:
...VILIP-1 (Visinin-Like Protein 1)
Introduction
Vilip 1 (Visinin Like Protein 1) Neuronal Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
VILIP-1 (Visinin-Like Protein 1), also known as VSNL1, is a neuronal calcium sensor protein that serves as a biomarker for neuronal injury in Alzheimer's disease and other neurodegenerative disorders[@laterza2006].
Overview
VILIP-1 belongs to the neuronal calcium sensor (NCS) family of proteins, which are expressed primarily in neurons and involved in calcium-dependent signaling pathways. In the brain, VILIP-1 is found in hippocampal pyramidal neurons, cortical neurons, and cerebellar granule cells[@bernstein1999]. CSF and plasma VILIP-1 levels reflect the degree of neuronal damage and have emerged as a promising biomarker for neurodegenerative diseases.
Structure and Function
Molecular Characteristics
| Property | Value |
|----------|-------|
| Gene | VSNL1 (Visinin-Like 1) |
| Protein Name | Visinin-like protein 1 (VILIP-1) |
| UniProt ID | P62760 |
| Molecular Weight | ~22 kDa |
| Brain Expression | Hippocampus, Cortex, Cerebellum |
| Cellular Localization | Cytosolic, membrane-associated |
Normal Physiological Function
VILIP-1 participates in several neuronal processes[@burgoyne2007]:
Calcium Signaling: Binds calcium with high affinity, acting as a calcium sensor
Neuroprotection: Exhibits neuroprotective properties against excitotoxicity
synaptic Transmission: Modulates neurotransmitter release
Gene Expression: May regulate transcription factors involved in neuronal survival
Phosphodiesterase Regulation: Activates cyclic nucleotide phosphodiesterasesRole as a Biomarker
CSF and Plasma VILIP-1
Elevated VILIP-1 in cerebrospinal fluid and blood indicates neuronal injury[@tarawneh2012][@lee2008]:
- Alzheimer's Disease: Significantly elevated in AD patients vs. controls
- Disease Progression: Levels correlate with cognitive decline and brain atrophy
- Diagnostic Accuracy: Helps differentiate AD from other dementias
- Prognostic Value: High levels predict faster disease progression
Clinical Significance
| Condition | CSF VILIP-1 Level | Clinical Interpretation |
|-----------|-------------------|------------------------|
| Alzheimer's Disease | ↑ Significantly elevated | Primary neuronal injury marker |
| MCI due to AD | ↑ Moderately elevated | Early neuronal damage |
| Vascular Dementia | ↑ Elevated | Ischemic neuronal injury |
| Parkinson's Disease | Normal to slightly elevated | Less cortical involvement |
| Frontotemporal Dementia | Variable | Depends on subtype |
| Healthy Controls | Low baseline | Normal neuronal integrity |
Mechanisms of Release
VILIP-1 is released into extracellular fluids through[@rohn2010]:
Neuronal Death: Direct release from dying neurons
Excitotoxicity: Glutamate-induced neuronal damage
Oxidative Stress: ROS-mediated neuronal injury
Synaptic Vesicle Release: Activity-dependent release
Blood-Brain Barrier Breakdown: Increased permeabilityDiagnostic Utility
Biomarker Panel
VILIP-1 is often combined with other biomarkers[@craigschapiro2011]:
| Biomarker | Primary Target | Sample Type |
|-----------|---------------|-------------|
| VILIP-1 | Neuronal injury | CSF, Plasma |
| p-tau | Tau pathology | CSF |
| Aβ42 | Amyloid pathology | CSF |
| NfL) | Axonal injury | CSF, Plasma |
| Neurogranin | Synaptic dysfunction | CSF |
- Sensitivity: 75-85% for AD detection
- Specificity: 70-80% vs. other dementias
- AUC: 0.75-0.85 in receiver operating characteristic analysis
Therapeutic Monitoring
Clinical Trials
VILIP-1 is used as a biomarker in AD therapeutic trials[@deters2011]:
- Anti-amyloid therapies: Aducanumab, Lecanemab, Donanemab
- Neuroprotective agents: Targeting neuronal survival pathways
- Disease-modifying treatments: Monitoring neuronal preservation
Treatment Response
Changes in VILIP-1 levels may indicate:
- Disease modification effectiveness
- Neuroprotective drug activity
- Need for treatment adjustment
Detection Methods
| Method | Sample | Advantages |
|--------|--------|------------|
| ELISA | CSF, Plasma | High throughput, validated |
| Simoa | Plasma | Ultra-sensitive for low concentrations |
| Western Blot | CSF | Confirmation of specific isoforms |
| Mass Spectrometry | CSF, Plasma | High specificity, multiplex capable |
Future Directions
Ongoing research is exploring the utility of VILIP-1 in blood-based biomarker panels for widespread clinical screening. Advances in ultrasensitive assay technologies have enabled reliable detection of VILIP-1 in plasma, expanding the feasibility of population-wide screening programs. Studies are investigating VILIP-1's potential for detecting prodromal Alzheimer's disease in asymptomatic individuals.
Emerging Applications
Recent studies have explored VILIP-1 in combination with other neuronal and glial biomarkers for enhanced diagnostic accuracy. The development of blood-based VILIP-1 assays has expanded clinical utility beyond CSF testing. Ongoing research focuses on establishing age-adjusted reference ranges and disease-specific cutoff values for clinical implementation.
Clinical Implementation
Preanalytical Considerations
Proper sample handling is critical for accurate VILIP-1 measurement. CSF samples should be collected using standardized protocols to avoid contamination with blood products. Centrifugation within 2 hours of collection and storage at -80°C are recommended to maintain biomarker stability. Plasma samples require similar careful handling with EDTA or heparin collection tubes.
Analytical Validation
Clinical implementation requires thorough analytical validation including assessment of intra-assay and inter-assay precision, dilution linearity, and sample stability. Reference laboratories have established quality control procedures to ensure consistent results across testing platforms.
Research Directions
Blood-Based Testing
The development of ultrasensitive immunoassays has enabled reliable detection of VILIP-1 in plasma and serum, significantly expanding clinical applicability. Several studies have demonstrated good correlation between CSF and blood VILIP-1 levels, supporting the use of blood-based testing for large-scale screening programs.
Personalized Medicine
VILIP-1 shows promise for personalized medicine applications in Alzheimer's disease, potentially guiding treatment decisions and monitoring therapeutic response. Integration with other biomarkers may enable more precise disease staging and prognosis.
Emerging Applications
Recent studies have explored VILIP-1 in combination with other neuronal and glial biomarkers for enhanced diagnostic accuracy. The development of blood-based VILIP-1 assays has expanded clinical utility beyond CSF testing. Ongoing research focuses on establishing age-adjusted reference ranges and disease-specific cutoff values for clinical implementation.
Background
The study of Vilip 1 (Visinin Like Protein 1) Neuronal Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Neuronal Injury Marker
Mermaid diagram (expand to render)
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
Cross-Links.jalz.2011.10.004)
External Links
- [Wikipedia - VILIP-1](/diseases/alzheimers-disease)
- [Parkinson's Disease
- [Biomarkers](/biomarkers)
- [Neuroinflammation](/mechanisms/neuroinflammation)
References
[Laterza OF, et al, Identification of novel brain biomarkers (2006)](https://pubmed.ncbi.nlm.nih.gov/17038176/))
[Bernstein HG, et al, Regional and cellular distribution of VILIP-1 in human brain (1999)](https://pubmed.ncbi.nlm.nih.gov/9927549/))
[Burgoyne RD, Neuronal calcium sensor proteins (2007)](https://pubmed.ncbi.nlm.nih.gov/17202136/))
[Tarawneh R, et al, VILIP-1 diagnostic utility in Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22801479/))
[Lee JM, et al, VILIP-1 in cerebrospinal fluid (2008)](https://pubmed.ncbi.nlm.nih.gov/17989456/))
[Rohn TT, et al, VILIP-1 expression in Alzheimer's disease brain (2010)](https://pubmed.ncbi.nlm.nih.gov/20097623/))
[Craig-Schapiro R, et al, VILIP-1 as a biomarker for AD (2011)](https://pubmed.ncbi.nlm.nih.gov/21228822/))
[Deters N, et al, VILIP-1 and cognitive decline (2011)](https://pubmed.ncbi.nlm.nih.gov/21566142/))